Poon R - Search Results

1

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Among authors: poon r. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.

2

Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management.

Poon RT, Fan ST, Lo CM, Liu CL, Ngan H, Ng IO, Wong J. Poon RT, et al. Am J Gastroenterol. 1999 Sep;94(9):2460-6. doi: 10.1111/j.1572-0241.1999.01376.x. Am J Gastroenterol. 1999. PMID: 10484009 Clinical Trial.

3

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.

Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Liu CL, et al. Among authors: poon rt. Am J Gastroenterol. 2000 Jan;95(1):218-22. doi: 10.1111/j.1572-0241.2000.01688.x. Am J Gastroenterol. 2000. PMID: 10638587 Clinical Trial.

4

Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.

Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Poon RT, et al. Cancer. 2000 Aug 1;89(3):500-7. Cancer. 2000. PMID: 10931448

5

Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.

Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ; EORTC Quality of Life Group. Blazeby JM, et al. Eur J Cancer. 2004 Nov;40(16):2439-44. doi: 10.1016/j.ejca.2004.06.033. Eur J Cancer. 2004. PMID: 15519517

6

Molecular pathways in hepatocellular carcinoma.

Pang R, Tse E, Poon RT. Pang R, et al. Among authors: poon rt. Cancer Lett. 2006 Aug 28;240(2):157-69. doi: 10.1016/j.canlet.2005.08.031. Epub 2005 Oct 17. Cancer Lett. 2006. PMID: 16239065 Review.

7

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.

Pang R, Poon RT. Pang R, et al. Among authors: poon rt. Cancer Lett. 2006 Oct 28;242(2):151-67. doi: 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 27. Cancer Lett. 2006. PMID: 16564617 Review.

8

Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.

Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT. Yau T, et al. Oncology. 2007;72 Suppl 1:67-71. doi: 10.1159/000111709. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087184

9

Biology of hepatocellular carcinoma.

Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Pang RW, et al. Ann Surg Oncol. 2008 Apr;15(4):962-71. doi: 10.1245/s10434-007-9730-z. Epub 2008 Jan 31. Ann Surg Oncol. 2008. PMID: 18236113 Review.

10

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.

Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT. Yau T, et al. Cancer. 2008 Nov 15;113(10):2742-51. doi: 10.1002/cncr.23878. Cancer. 2008. PMID: 18853421 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

872 results

Search Page